Reuters logo
BRIEF-Syros Pharmaceuticals Q4 loss per share $0.47
March 20, 2017 / 12:33 PM / 8 months ago

BRIEF-Syros Pharmaceuticals Q4 loss per share $0.47

March 20 (Reuters) - Syros Pharmaceuticals Inc:

* Syros reports fourth quarter and full year 2016 financial results and highlights key accomplishments and upcoming milestones

* Q4 loss per share $0.47

* Q4 earnings per share view $-0.64 -- Thomson Reuters I/B/E/S

* Syros Pharmaceuticals Inc -on track to report initial clinical data on sy-1425 in fall 2017

* Syros Pharmaceuticals Inc -on track to initiate phase 1 clinical trial of sy-1365 in transcriptionally driven solid tumors in Q2 of 2017

* Syros Pharmaceuticals Inc- expects that its cash-based operating expenses on a non-gaap basis will be approximately $50 million for fiscal year 2017

* Syros Pharmaceuticals-expects current cash and balance will be sufficient to fund its operating expenses and capital expenditure requirements into mid-2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below